Filing Details

Accession Number:
0001179110-19-003505
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-07 15:19:02
Reporting Period:
2019-03-07
Accepted Time:
2019-03-07 15:19:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1578845 Allergan Plc AGN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1268854 L Brent Saunders Clonshaugh Business And Technology Park,
Coolock, Co.
Dublin L2 D17 E400
Chairman, President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value $0.0001 Acquisiton 2019-03-07 300 $142.18 169,206 No 4 P Direct
Ordinary Shares, Par Value $0.0001 Acquisiton 2019-03-07 860 $143.70 170,066 No 4 P Direct
Ordinary Shares, Par Value $0.0001 Acquisiton 2019-03-07 600 $144.37 170,666 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $142.09 to $142.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $143.13 to $143.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $144.15 to $144.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.